Clinical calculator summary
2002 five-factor MSKCC/Motzer prognostic model
Clinical calculator summary
2002 five-factor MSKCC/Motzer prognostic model
A five-factor additive prognostic classification for previously untreated advanced or metastatic RCC.
Evidence-based context for fast calculator use
- Purpose:
- Assign the favorable, intermediate, or poor 2002 MSKCC prognostic group.
- Population:
- Advanced or metastatic RCC before first systemic therapy; displayed outcomes are historical first-line interferon-era cohort medians.
- Factors:
- KPS <80%, LDH >1.5 x ULN, Hemoglobin < LLN, Corrected calcium >10 mg/dL, Diagnosis-to-treatment interval <1 year
- Reference:
- Motzer et al., JCO 2002; external validation by Mekhail et al., JCO 2005.
Pin your most used calculators here by clicking the star in the dropdown.
MSKCC (Motzer) Score
Clinical Context & Background
This calculator implements the five-factor 2002 MSKCC/Motzer model for previously systemically untreated advanced or metastatic renal cell carcinoma receiving first-line interferon-alfa-containing therapy.
One adverse point is assigned for KPS below 80%, LDH above 1.5 times the institutional assay upper limit of normal, hemoglobin below the institutional or sex-specific lower limit of normal, corrected calcium above 10 mg/dL (approximately 2.5 mmol/L), and less than one year from diagnosis to first-line treatment. Equality at each threshold is non-adverse.
The displayed 30, 14, and 5 month median overall-survival values are rounded historical group outcomes from the first-line interferon-era cohort. They are not modern individualized survival predictions or a treatment-selection rule. This implementation does not mix the 1999 nephrectomy model, Cleveland Clinic expansion, or IMDC criteria.
Formula Logic
MSKCC score = number of adverse factors present (1 point each; total 0-5)Reference Data
| Risk Group | Number of Risk Factors | 2002 First-Line Interferon-Era Median OS |
|---|---|---|
| Favorable Risk | 0 | 30 months (29.6; 95% CI 20.9-37.8) |
| Intermediate Risk | 1-2 | 14 months (13.8; 95% CI 12.4-15.9) |
| Poor Risk | 3-5 | 5 months (4.9; 95% CI 4.3-6.3) |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use for historical pretreatment prognostic stratification in advanced or metastatic RCC when all five baseline criteria are known.
- Use the institutional assay ULN for LDH and institutional or sex-specific LLN for hemoglobin; corrected calcium uses the fixed 10 mg/dL model cutoff.
How To Interpret
- Zero adverse factors is favorable, one or two is intermediate, and three to five is poor risk.
- The survival values are historical first-line interferon-era group medians, not individualized contemporary forecasts.
What To Do Next
- Document all five baseline findings, the reference limits used, score, and risk group.
- Use current RCC guidance and individualized clinical assessment for treatment decisions rather than this score alone.
Limitations
- Not a contemporary treatment-selection rule and not validated for localized RCC or postoperative recurrence prediction.
- The derivation cohort predates targeted therapy and immune-checkpoint combinations.
- Do not substitute IMDC calcium-above-ULN semantics for the fixed MSKCC corrected-calcium cutoff.
Validated Population
Previously systemically untreated advanced or metastatic RCC assessed before first-line interferon-alfa-containing therapy.
Group assignment
Two adverse factors produce an MSKCC score of 2 and the Intermediate Risk group.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Three source-backed cases passed through visible production controls at MSKCC scores 0, 2, and 5.
- Favorable, Intermediate, and Poor groups rendered without the former generic risk gauge.
- No unexpected N/A, literal undefined value, stale control, unsupported gauge, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/mskcc-rcc-2026-08-03.json.
: Local browser remediation
- Valid MSKCC/Motzer results now explicitly suppress the shared generic risk gauge so Favorable, Intermediate, and Poor source terminology is not relabeled.
- Ten source-backed cases passed through visible local browser controls across 11 submissions, covering scores 0-5, every factor, all three groups, required-field validation, and reset/repeat behavior.
- The existing calculator-specific audit passed 1,116/1,116. Production status remains open until this commit is deployed and the public route is revalidated.
Local case-level remediation evidence is retained in validation/browser-production/mskcc-rcc.local-remediation.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-ui-console. medium: Every valid result adds generic Low Risk / Intermediate / High Risk terminology instead of the source-defined Favorable / Intermediate / Poor groups. | medium: Production emitted minified React error #418 during route loads and interactions.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/mskcc-rcc.json.
: Full validation test
- Verified 32/32 factor combinations, ten exact source boundaries, 110 malformed standalone inputs, and 964 renal-panel component parity and isolation cases; 1,116/1,116 checks passed.
: Correction history
- Removed favorable defaults and coercive values, required all five exact criteria, added the complete five-factor trace and matched row, identified outcomes as historical first-line interferon-era group medians, removed treatment-selection claims, and separated the renal panel's MSKCC fixed calcium cutoff from IMDC institutional-ULN calcium.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
Are values equal to a threshold adverse?
No. KPS 80%, LDH exactly 1.5 x ULN, hemoglobin at LLN, corrected calcium 10 mg/dL, and exactly one year are non-adverse.
Is the calcium threshold the institutional ULN?
No. The 2002 MSKCC model uses corrected calcium above the fixed cutoff of 10 mg/dL, approximately 2.5 mmol/L.
Do the survival medians predict an individual patient’s current outcome?
No. They are historical group medians from a first-line interferon-era cohort.
Evidence-based oncology decision support. Verify with clinical guidelines.